Moreover, MLL frequently hosts international research cooperation directly: For instance through exchange programs, our test procedures and data repositories, but also by allowing guest researchers to shadow the work of our facility and by sitting on national and international work groups.

We also support research institutions around the world to produce new insight in the field of leukemia diagnostics and emergence, as well as in the rollout of new procedures and applications for routine diagnostics in the facilities themselves.


Our research findings are published in international, peer-reviewed journals and feature in conference talks and lectures, as well as in poster presentations and at scientific events.

Gentner E, Vegi NM, Mulaw MA, Mandal T, Bamezai S, Claus R, Tasdogan A, Quintanilla-Martinez L, Grunenberg A, Döhner K, Döhner H, Bullinger L, Haferlach T, Buske C, Rawat VP, Feuring-Buske M. VENTX induces expansion of primitive erythroid cells and contributes to the development of acute myeloid leukemia in mice. Oncotarget. 2016;7(52):86889-86901.

Gratwohl A, Pfirrmann M, Zander A, Kröger N, Beelen D, Novotny J, Nerl C, Scheid C, Spiekermann K, Mayer J, Sayer HG, Falge C, Bunjes D, Döhner H, Ganser A, Schmidt-Wolf I, Schwerdtfeger R, Baurmann H, Kuse R, Schmitz N, Wehmeier A, Fischer JT, Ho AD, Wilhelm M, Goebeler ME, Lindemann HW, Bormann M, Hertenstein B, Schlimok G, Baerlocher GM, Aul C, Pfreundschuh M, Fabian M, Staib P, Edinger M, Schatz M, Fauser A, Arnold R, Kindler T, Wulf G, Rosselet A, Hellmann A, Schäfer E, Prümmer O, Schenk M, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Büsche G, Haferlach C, Schnittger S, Müller MC, Reiter A, Berger U, Saußele S, Hochhaus A, Hehlmann R. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia-A randomized comparison of stem cell transplantation with drug treatment. Leukemia. 2016;30(3):562-9.

Groepper S, Schlue J, Haferlach C, Giagounidis A. Transfusion Independency and Histological Remission in a Patient with Advanced Primary Myelofibrosis Receiving Iron-Chelation Therapy with Deferasirox. Oncol Res Treat. 2016;39(6):384-387.

Gyárfás T, Wintgens J, Biskup W, Oschlies I, Klapper W, Siebert R, Bens S, Haferlach C, Meisel R, Kuhlen M, Borkhardt A. Transient spontaneous remission in congenital MLL-AF10 rearranged acute myeloid leukemia presenting with cardiorespiratory failure and meconium ileus. Mol Cell Pediatr. 2016;3(1):30.

Haberl S, Haferlach T, Stengel A, Jeromin S, Kern W, Haferlach C.MYC rearranged B-cell neoplasms: Impact of genetics on classification. Cancer Genet. 2016;209(10):431-439.

Haferlach T, Stengel A, Eckstein S, Perglerová K, Alpermann T, Kern W, Haferlach C, Meggendorfer M. The new provisional WHO entity 'RUNX1 mutated AML' shows specific genetics but no prognostic influence of dysplasia. Leukemia. 2016;30(10):2109-2112.

Haferlach T, Weber S, Konietschke R, Nadarajah N, Stengel A, Kern W, Haferlach C, Meggendorfer M. Robustness of comprehensive DNA and RNA based assays at diagnosis of acute myeloid leukemia using blood and bone marrow stored on filter cards. Leukemia. 2016;30(10):2123-2125.

Harrach S, Schmidt-Lauber C, Pap T, Pavenstädt H, Schlatter E, Schmidt E, Berdel WE, Schulze U, Edemir B, Jeromin S, Haferlach T, Ciarimboli G, Bertrand J. MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients. Blood Cancer J. 2016;6(9):e470.

Hourigan C, Haferlach T, Hokland P. Cord-Blood Transplantation in Patients with Minimal Residual Disease. N Engl J Med. 2016;375(22):2203-2205.

Jawhar M, Schwaab J, Schnittger S, Meggendorfer M, Pfirrmann M, Sotlar K, Horny HP, Metzgeroth G, Kluger S, Naumann N, Haferlach C, Haferlach T, Valent P, Hofmann WK, Fabarius A, Cross NC, Reiter A. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high risk group of patients with KIT D816V+ advanced systemic mastocytosis. Leukemia. 2016;30(1):136-43.

2 / 5